

Drug Repurposing Guidebook

Building Block 1442

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	Competitive intelligence
References	Open-source competitive intelligence software or online tools: 1/ Governmental tools US tools: [1] Pubmed https://pubmed.ncbi.nlm.nih.gov/ [2] NIH tool https://www.nlm.nih.gov/services/databases_subject.html [3] FDA tool https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases EU tools: [4] Data Europe: https://data.europa.eu/en the official portal for European data [5] European Galaxy Server: https://usegalaxy.eu , the open, reproducible, web-based platform for data intensive research 2/ Commercial or OSINT software from non-governmental organisations: [6] Google analytics: https://analytics.google.com [7] Babel X - Al-enabled data aggregation and analysis [8] Maltego - Interactive datamining with rich visualization showing relationships between different data in the collection In IP, for freedom-to-operate studies: [9] https://clarivate.com/ [10] https://www.inquartik.com/ [11] https://www.lens.org/lens/
Description	"Competitive intelligence" software or tools consist in gathering and analysing information related to research discovery, biopharma,



ITEM	DESCRIPTION
	medtech, IP matters or real-world data intelligence in the life science field. On one side, governmental organisations developed "open-source intelligence (OSINT)" that can be used for free. On the other hand, non-governmental organisations or companies developed their own tools or software [6-8] with specific software and databases for IP matters and freedom-to-operate studies [9-11].
Category	Compound and network databases and tools to use them
Туре	Development practice
Geographical scope	International
Availability	Open source or access, and; Commercial software/tool restricted to the payers
Scope of use	 Basic Research investigations Drug development Clinical studies Market studies
Stakeholders involved	Researchers, bioinformaticians, data scientists, From academia or industry Consultants in IP, innovation
Enablers/ Requirements	Basic researchers in chemistry, pharmacologists, bio-informaticians, data scientists Drug developers from academia or industry
Output	New knowledge for faster drug development Discovery of new targets for a RD Discovery of new applications for a drug Freedom-to-operate studies
Best time to apply and time window	At all stages of drug development.
Expert tips	PROs: Open-source competitive intelligence tools are accessible to all stakeholders



ITEM	DESCRIPTION
	CONs: commercial software are usually very expensive for academia and can be used only by companies. The competitive intelligence software must be used by specific experts (data scientists, IP expert)